Research
Hormonal
Obesity has a compelling influence on fertility and reproductive health.
Healthcare practitioners should consider the impact of obesity on reproductive health when treating patients.
StrongSupportsmedium confidence
The pervasive effects of this worldwide health predicament are both direct and indirect, having a compelling influence on fertility.
Why this rating
The review aggregates current evidence, indicating a comprehensive analysis.
Source
Reproduction and Anti-Obesity Medications: A Review of Current Evidence
Héctor Iván Saldívar-Cerón · The Journal of Reproduction · 2023
DOI 10.58779/issn.2954-467x.tjor2023.v2.n2.27
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →